Article Text

PDF
Left ventricular assist devices
  1. E J Birks
  1. Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, UK
  1. Correspondence to Dr E J Birks, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK; e.birks{at}imperial.ac.uk

Abstract

Left ventricular assist device (LVAD) insertion in patients with advanced heart failure with deteriorating clinical status is life saving, and LVADs are now being inserted into an increasing number of patients with advanced heart failure. They were initially inserted as a bridge to transplantation, and the decreased availability of donor hearts means that an increasing number of patients are requiring LVAD support for survival when their clinical status deteriorates. There is strong evidence that with LVAD unloading, particularly when combined with pharmacological treatment, the patients’ myocardial function can also recover, allowing device removal and avoiding the need for transplantation, immunosuppression and its associated complications. This indication, known as “bridge to recovery” is a newer and expanding indication. The future use of LVADs, particularly as survival continues to increase, is extending to their wider use as destination therapy, when the device is inserted lifelong as an alternative to transplantation, and this role is likely to increase further. LVAD technology is evolving quickly, survival is improving, the incidence of complications is decreasing and durability of the devices is improving.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and Peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.